Abstract
Pharmaceutical Patent AnalystVol. 4, No. 3 Hot TopicExtension of Bolar exemption law: what will this mean for UK drug research?Stephen Bennett & Ian MossStephen Bennett*Author for correspondence: E-mail Address: stephen.bennett@hoganlovells.com Hogan Lovells International LLP, Atlantic House, Holborn Viaduct, London, EC1A 2FGSearch for more papers by this author & Ian Moss Hogan Lovells International LLP, Atlantic House, Holborn Viaduct, London, EC1A 2FGSearch for more papers by this authorPublished Online:1 Jun 2015https://doi.org/10.4155/ppa.15.5AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleReferences1 21 U.S.C. § 355(j).Google Scholar2 Roche Products, Inc. v. Bolar Pharmaceutical Co., 733 F.2d 858 (Fed. Cir.) (1984).Google Scholar3 Experimental use and Bolar Exception, Impact Assessment No: BIS0402. www.parliament.uk.Google Scholar4 The Review and Refresh of Bioscience 2015: a report to government by the bioscience innovation and growth team. http://webarchive.nationalarchives.gov.uk.Google Scholar5 Changes to patents legislation made by the Legislative Reform (Patents) Order 2014 from 1 October 2014, UKIPO. (Available: www.gov.uk.Google Scholar6 Astellas Pharma Inc. v. Polpharma SA Pharmaceutical Works., Docket Number IV CSK 92/13 (2013).Google Scholar7 Astellas Pharma Inc. v. Polpharma SA Pharmaceutical Works., Case C-661/13 (2014).Google ScholarFiguresReferencesRelatedDetails Vol. 4, No. 3 Follow us on social media for the latest updates Metrics Downloaded 62 times History Published online 1 June 2015 Published in print May 2015 Information© Future Science LtdFinancial & competing interests disclosureThe authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
